Don’t miss the latest developments in business and finance.

Dr Reddys Laboratories launches Carmustine for Injection in US market

Image
Capital Market
Last Updated : Oct 16 2021 | 1:04 PM IST
Dr Reddys Laboratories announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health.

Dr. Reddy's Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.

Powered by Capital Market - Live News

Also Read

First Published: Oct 16 2021 | 12:51 PM IST

Next Story